Common Reasons for Request for Supplemental Information in Overseas Registration of Dental Devices

Common reasons for requests for supplemental information (RFI) in overseas registration of dental devices include incorrect product classification, incomplete technical documentation, insufficient risk management and performance verification evidence, labeling and instructions for use (IFU) not meeting target country requirements, quality management system certificates not being recognized, and improper local agent or authorized representative arrangements. Companies should first determine the risk classification of the dental device under the target country's regulatory framework, then identify the applicable registration pathway. Subsequently, they should review existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation to distinguish what can be reused from what must be regenerated according to local regulations. Common RFI items include unclear product description and intended purpose, inapplicable biocompatibility test reports, insufficient sterilization validation parameters, weak clinical evaluation evidence chains, and labels missing local language or special warning symbols. To avoid repeated RFI, it is recommended to conduct a point-by-point pre-submission review against GHWP member state or target-country specific requirements, build a core technical document package, and confirm submission strategy and post-market obligations together with an experienced local agent. RFI not only prolongs timelines but also affects registration costs and market entry windows; companies should reserve adequate time for a complete evidence chain and localization conversion during the project initiation phase. This information is compiled based on AIMEILI's registration practice question bank, the medical device international registration knowledge base, and publicly available regulatory information; specific projects should be based on the target country regulatory authority's latest requirements and product-specific documentation.

Overview

Overseas registration of dental devices is a critical step for manufacturers entering international markets. Dental devices covered in this discussion include dental treatment units, dental handpieces, scalers, endodontic instruments, dental implants, orthodontic brackets, and other active, non-active, and implantable products. Regulatory approaches for dental devices vary significantly across countries, and registration document requirements differ accordingly.

After submitting a registration application, companies often receive RFI notices from regulatory authorities or authorized representatives. RFI is not merely a request for document modification but a demand for further evidence of product safety and effectiveness. Common reasons for RFI share commonalities, such as incorrect product classification, insufficient applicability of technical documents, test reports not meeting local standards, and defects in labeling and IFU.

RFI not only affects registration progress but also delays market entry and increases both time and costs. When repeated RFI cycles fail to resolve issues, the application may be rejected. Therefore, companies need to systematically understand the registration logic and evidence requirements of target markets before submission to avoid unnecessary detours.

Registration Decision Logic

When approaching an overseas registration project, the first step is to determine whether the product falls within the scope of medical device regulation in that country. Most dental devices are medical devices, but some products, such as teeth whitening materials or oral cleaning products, may be classified as cosmetics or general consumer goods, which requires a case-by-case determination based on the target market's regulatory definitions.

Once classified as a medical device, companies must further determine the product's risk class. For example, the EU MDR classifies products into Class I, IIa, IIb, and III; the US FDA classifies by product category; and GHWP member states in Southeast Asia have their own classification rules. The risk class directly determines whether the registration pathway is self-declaration, product registration, or premarket approval.

After determining the registration pathway, companies should assess the reusability of existing documentation. Materials from NMPA registration, CE certification, FDA clearance/approval, or MDSAP audits can serve as a foundational base. However, differences across markets in clinical evidence, biocompatibility, sterilization validation, and labeling requirements mean documents cannot be directly copied without adaptation.

When registering in GHWP member states, it is often possible to submit a single core technical document package, with localization adjustments according to each country's requirements. Companies should first establish a quality system document library covering product design, risk management, performance verification, and clinical evaluation, and then supplement country-specific regulatory requirements.

Documentation and Evidence

Registration dossiers typically include product technical documentation, risk management reports, performance test reports, biocompatibility reports, sterilization validation reports, clinical evaluation materials, labeling and IFU, and quality system certificates. Each module could become the subject of an RFI.

Product description and intended purpose must be clear and accurate. Regulatory authorities often require companies to further clarify indications, target population, environment of use, and operating instructions. If the intended purpose includes therapeutic, diagnostic, or preventive functions, corresponding clinical or performance evidence must be provided.

Risk management is a core document in the registration dossier. Companies must establish a complete risk management process in accordance with ISO 14971, and ensure that risk analysis, risk evaluation, risk control measures, and verification results are cross-referenced. If the risk management report simply presents tables without product-specific analysis, it is highly likely to trigger an RFI.

Common issues in the performance verification section include test methods not conforming to target country standards, or insufficient sample sizes. Mechanical performance, electrical safety, biocompatibility, and chemical properties of dental devices must be tested in accordance with relevant ISO standards or target country standards, with qualified test reports provided.

For higher-risk products such as dental implants and orthodontic materials, clinical evaluation is a frequent RFI area. Companies need to choose among clinical literature review, clinical data evaluation, or clinical trial pathways based on the target country's regulations. If using the literature pathway, equivalence between literature data and the product must be demonstrated.

Labeling and IFU are often overlooked in overseas registration. Language, units of measurement, warning symbols, sterilization marks, expiry dates, manufacturing dates, and manufacturer and agent information must all comply with local requirements. Some countries also require electronic IFU or specific formatting adjustments.

Regarding quality management system certificates, holding only an ISO 13485 certificate may not cover all target markets. Some countries require a quality system audit report compliant with local regulations, or submission of MDSAP audit results. Companies must verify the scope and validity of the certificate.

A local agent or authorized representative is mandatory in most markets. Companies must provide the authorization agreement, agent information, and corresponding supporting documents. If the agent's qualifications or authorization scope do not meet requirements, an RFI will be issued.

Common Mistakes

• Incorrect product classification leads to an inappropriate registration pathway, e.g., submitting a Class II product as Class I, resulting in direct rejection by the regulatory authority.
• The technical documentation is directly used from another country's English version without translation into the target country's language, or translation quality is poor and causes ambiguity.
• Performance tests are not conducted according to target country standards; using internal control standards or domestic standards leads to non-acceptance of the test report.
• The risk management report is incomplete; hazard scenario analysis is missing, and risk control measures are not linked to verification results.
• The biocompatibility test report uses materials or test conditions inconsistent with the actual product, e.g., not covering the final sterilized state.
• Clinical evaluation evidence is insufficient; the literature search strategy is unreasonable, and equivalence with similar products is not demonstrated.
• The label or IFU lacks information or symbols required by the target country, e.g., missing specific warnings, or CE mark without a Notified Body number.
• Local agent and authorized representative requirements are neglected; necessary authorization letters or documents in the local format are not provided.

Company Preparation Checklist

• Confirm the regulatory classification of the product under the target country's regulations, and consult dental-device-specific guidance documents.
• Establish a cross-functional registration team including regulatory, R&D, quality, clinical, production, and marketing personnel to ensure consistency of information.
• Build a core technical document package covering product technical requirements, design verification, risk management, clinical evaluation, labeling and IFU, for multipurpose reuse across countries.
• Review the validity of existing reports against target country requirements, including test standards, sample sizes, laboratory qualifications, and report dates.
• Complete localized translation of labels and IFU early, and have them reviewed by a local regulatory consultant.
• Clarify quality system certificate requirements; arrange for MDSAP audits or supplementary local quality system certifications in advance if necessary.
• Sign a formal agreement with an experienced local agent, clearly defining the scope of authorization, change notifications, and post-market responsibilities.
• Develop an RFI response process, keep records of communications with regulatory authorities, and respond efficiently within the deadline.

AIMEILI Insights

In dental device overseas registration projects, the most common misjudgment is underestimating the differences in target country regulations. Many companies assume that holding a CE or FDA certificate allows direct entry into other markets, but in reality each country has independent registration requirements and review priorities. Even within GHWP member states, mutual recognition is not complete.

In the early stages of a project, companies should conduct a target market regulatory landscape assessment rather than rush to authorize an agent to submit. We recommend holding a registration strategy meeting with regulatory consultants and a local agent at project initiation to clarify product classification, registration pathway, test standards, and evidence gaps, and to generate a written gap analysis report.

Document reuse should distinguish between a base layer and a localization layer. General documentation such as product design, risk analysis, basic performance data, and ISO 13485 certificates can be reused. Clinical evaluation literature, label formats, country-specific test reports, and authorized agent documents must be prepared according to local regulations. Localization is not simple translation; it is the transformation of technical language into normative expressions accepted by the local regulatory authority.

The role of the local agent should not be limited to dossier submission. Change controls after certificate issuance, periodic updates, post-market surveillance, and certificate renewals all depend on the agent. Frequent changes of agents, or an irresponsible agent, will directly affect the ongoing validity of the certificate.

For multi-country registration, avoid creating a separate dossier for each country. Instead, establish one 'source document package' and generate 'submission versions' for different markets. This reduces duplication of work and minimizes RFI risk caused by version confusion.

Frequently Asked Questions

Is an RFI notice usually sent multiple times? What is the maximum number of RFI cycles?

Regulations vary by market. Regulatory authorities typically allow one or more RFI opportunities, each with a submission deadline. If after several RFI cycles the applicant still cannot provide valid evidence, the application may be rejected. Therefore, we recommend a comprehensive pre-submission review to pass on the first attempt.

Do dental implants necessarily require clinical data?

Dental implants are considered higher-risk devices, and most countries require sufficient clinical evaluation data. If the product design and materials are equivalent to a legally marketed device, a literature- and clinical-data-based evaluation pathway may be accepted. If equivalence cannot be demonstrated, or if novel materials or new intended purposes are involved, a clinical trial may be required.

Do registration documents for foreign manufacturers need notarization or translation?

Almost all countries require registration documents to be translated into the local official language, and some also require notarization or legalization of the translation. Some Latin American and Middle Eastern countries additionally require the manufacturer's qualification documents to undergo apostille or embassy/consulate legalization. Companies should allocate sufficient time for translation and legalization.

Can a company start registration in other countries while an RFI is pending in one country?

Yes. An RFI is specific to the pending application in that country and does not affect registration activities in other countries. However, when initiating multi-country registration, it is advisable to first identify common issues from pending RFIs in other countries to avoid the same issues in new submissions.

Continue Reading

• Previous: How to Choose a Local Agent for Overseas Registration of Dental Devices?
• Next: What Preparations Are Needed Before Renewing Overseas Registration of Patient Monitoring Equipment?

Recommended Reading

• Risk Management Documentation Requirements for Overseas Registration of Imaging Devices
• How to Prepare Performance Verification Materials for Overseas Registration of Implantable Products
• How to Prepare Registration Dossiers for Dental Devices?
• How to Choose a Local Agent for Overseas Registration of Dental Devices?
• What Preparations Are Needed Before Renewing Overseas Registration of Patient Monitoring Equipment?
• How Are Authorized Representative Responsibilities Divided in Overseas Registration of Rehabilitation Equipment?

About AIMEILI

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory authorities, international organizations, standard-setting bodies, and publicly available regulatory materials; industry media and project experience are used as auxiliary references. Applicability boundary: This article is for preliminary understanding, document preparation, and project planning and does not replace the formal requirements, test conclusions, or legal advice of target country regulatory authorities.